司美格鲁肽再添新功效！这个作用机制太惊艳了！

Core Insights - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life without being affected by individual patient characteristics [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD, regardless of diabetes duration, BMI, or blood sugar control [10][12][13][14]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that all patient subgroups benefited from Semaglutide treatment [9][10]. - The study revealed that the improvement in walking ability was independent of weight loss and blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Clinical Implications - The findings indicate that Semaglutide can serve as a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb blood circulation and functional capacity [20][21]. - The safety profile of Semaglutide was comparable to that of the placebo group, with no significant increase in adverse events, including hypoglycemia [18][19]. - This research opens new avenues for treating the challenging combination of diabetes and PAD, providing valuable clinical guidance [21].